Trials, sites and PTA approach
| HPTN trial/site (clinicaltrial.gov identifier) | Investigational intervention | PTA approach |
| 052/India (NCT00074581) | Early initiation of ART to delay AIDS | ARTs were not freely available when the study started, yet the study committed to providing PTA to ARTs for participants post-trial for a length of time equal to that of their trial participation; ARTs were freely available through local health system when the study concluded and participants were referred to local clinics. |
| 058/China (NCT00270257) | Suboxone and counselling to decrease drug use and prevent HIV | Manufacturer agreed to provide Suboxone with the intent to allow participants to complete a full course of opioid substitution therapy with Suboxone, yet the study ended early and trial sites did not have funding or capacity to offer PTA; participants were referred to methadone clinic. |
| 067/USA (NCT01327651) | Intermittent dosing of pre-exposure prophylaxis | Participants were referred to health providers for continued access to pre-exposure prophylaxis; had option of continuing to be seen at the trial sites. |
| 069/USA (NCT01505114) | Four different oral pre-exposure prophylaxis regimens | At initial study planning, no regimen was yet approved for prevention and no PTA plan was specified in the protocol. Truvada was approved for pre-exposure prophylaxis during study and as participants were nearing completion of study visits, those who wished to continue pre-exposure prophylaxis were referred to healthcare providers. |
| 073/USA (NCT01808352) | Open-label pre-exposure prophylaxis for black men who have sex with men | Participants were referred to local care providers to continue access to Truvada pre-exposure prophylaxis through the healthcare system. |
| 083/USA (NCT02720094) | Long-acting injectable PrEP (phase IIb/3) | None specified in the protocol. |
ARTs, antiretroviral therapies; HPTN, HIV Prevention Trials Network; PrEP, pre-exposure prophylaxis; PTA, post-trial access.